Expression of endothelin receptor subtypes in bronchial tumors

Oncology Reports

Volumn 23, Issue 2, 2010, Pages 457-463

  Blouquit Laye, Sabine ^a   Regnier, Agathe ^b   Beauchet, Alain ^b   Zimmermann, Ute ^b   Devillier, Philippe ^a   Chinet, Thierry ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Carcinoma; Endothelin 1; Immunohistochemistry; Lung; Receptors

Indexed keywords

ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR;

ADULT; ARTICLE; CELL GROWTH; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION;

AGED; CARCINOMA, BRONCHOGENIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN ISOFORMS; RECEPTORS, ENDOTHELIN; RESPIRATORY MUCOSA; SMOKING; TISSUE DISTRIBUTION;

EID: 76649098572     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000655     Document Type: Article

References (47)

1. Motte S, McEntee K and Naeije R: Endothelin receptor antagonists. Pharmacol Ther 110: 386-414, 2006.
2. Spieker LE, Noll G, Ruschitzka FT and Lüscher TF: Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched? Heart Fail Rev 6: 301-315, 2001.
3. Michael JR and Markewitz B: Endothelins and the lung. Am J Respir Crit Care Med 154: 555-581, 1996.
4. Baraniuk JN, Molet S, Mullol J and Naranch K: Endothelin and the airway mucosa. Pulm Pharmacol Ther 11: 113-123, 1998.
5. Marciniak SJ, Plumpton C, Barker PJ, Huskisson NS and Davenport AP: Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmacol 5: 175-182, 1992.
6. Blouquit S, Sari A, Lombet A, D'Herbomez M, Naline E, Matran R and Chinet T: Effects of Endothelin-1 on epithelial ion transport in human airways. Am J Respir Cell Mol Biol 29: 245-251, 2003.
7. Jacobs A, Preston IR and Gomberg-Maitland M: Endothelin receptor antagonism in pulmonary arterial hypertension: a role for selective ET(A) inhibition? Curr Med Res Opin 22: 2567-2574, 2006.
8. Sato K, Oka, M, Hasunuma K, Ohnishi M, Sato K and Kira S: Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 269: L668-L672, 1995.
9. Kizawa Y, Ohuchi N, Saito K, Kusama T and Murakami H: Effects of endothelin-1 and nitric oxide on proliferation of cultured guinea pig bronchial smooth muscle cells. Comp Biochem Physiol C Toxicol Pharmacol 128: 495-501, 2001.
10. Morbidelli L, Orlando C, Maggi CA, Ledda F and Ziche M: Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 269: H686-H695, 1995.
11. Murlas CG, Gulati A, Singh G and Najmabadi F: Endothelin-1 stimulates proliferation of normal airway epithelial cells. Biochem Biophys Res Commun 212: 953-959, 1995.
12. Ninomiya H, Inui T and Masaki T: Paracrine endothelin signaling in the control of basal cell proliferation in guinea pig tracheal epithelium. J Pharmacol Exp Ther 286: 469-480, 1998.
13. Adner M, Cardell LO, Sjöberg T, Ottosson A and Edvinsson L: Contractile endothelin-B (ETB) receptors in human small bronchi. Eur Respir J 9: 351-355, 1996.
14. Daher Z, Noël J and Claing A: Endothelin-1 promotes migration of endothelial cells through the activation of ARF6 and the regulation of FAK activity. Cell Signal 20: 2256-2265, 2008.
15. Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ and Webb DJ: Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92: 2148-2152, 2005.
16. Dupuis J, Stewart DJ, Cernacek P and Gosselin G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94: 1578-1584, 1996.
17. Bagnato A, Tecce R, Moretti C, Di castro V, Spergel D and Catt KJ: Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1: 1059-1066, 1995.
18. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, Burnstock G and Taylor I: Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET (A) receptor antagonism. Br J Cancer 85: 1759-1763, 2001.
19. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS and Simons JW: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56: 663-668, 1996.
20. Bagnato A and Natali PG: Endothelin receptors as novel targets in tumor therapy. J Transl Med 2: 16, 2004.
21. Herrmann E, Eltze E, Bierer S, Bogemann M, Brinkmann OA, Balnowair H, Hertle L and Wülfing C: Expression of the endothelin-axis in the different histologic subtypes of renal cell carcinoma: a tissue microarray analysis. Oncol Rep 17: 275-280, 2007.
22. Wülfing C, Eltze E, Yamini J, Bierer S, Böcker W, Hertle L, Semjonow A and Sievert KD: Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival. Eur Urol 47: 593-600, 2005.
23. Ahmed SI, Thompson J, Coulson JM and Woll PJ: Studies on the expression of endothelin, its receptors subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol 22: 422-431, 2000.
24. Giaid A, Hamid QA, Springall DR, Yanagisawa M, Shinmi O, Sawamura T, Masaki T, Kimura S, Corrin B and Polak JM: Detection of endothelin immunoreactivity and mRNA in pulmonary tumours. J Pathol 162: 15-22, 1990.
25. Boldrini L, Gisfredi S, Ursino S, Faviana P, Lucchi M, Melfi F, Mussi A, Basolo F and Fontanini G: Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer 41: 2828-2835, 2005.
26. Carpagnano GE, Foschino-Barbaro MP, Resta O, Gramiccioni E and Carpagnano F: Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer. Oncology 66: 180-184, 2004.
27. Pickering V, Jordan RC and Schmidt BL: Elevated salivary endothelin levels in oral cancer patients: A pilot study. Oral Oncol 43: 37-41, 2007.
28. Grant K, Knowles J, Dawas K, Burnstock G, Taylor I and Loizidou M: Mechanisms of endothelin 1-stimulated proliferation in colorectal cancer cell lines. Br J Surg 94: 106-112, 2007.
29. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B and Nanus DM: Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 106: 1399-1407, 2000.
30. Bagnato A, Rosano L, Spinella F, Di Castro V, Tecce R and Natali PG: Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 64: 1436-1443, 2004.
31. Rayhman O, Klipper E, Muller L, Davidson B, Reich R and Meidan R: Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res 68: 9265-9273, 2008.
32. Wülfing P, Kersting C, Tio J, Fischer RJ, Wülfing C, Poremba C, Diallo R, Böcker W and Kiesel L: Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 10: 2393-2400, 2004.
33. Knott PG, D'Aprile AC, Henry PJ, Hay DW and Goldie RG: Receptors for endothelin-1 in asthmatic human peripheral lung. Br J Pharmacol 114: 1-3, 1995.
34. Goldie RG, Henry PJ, Knott PG, Self GJ, Luttmann MA and Hay DW: Endothelin-1 receptor density, distribution, and function in human isolated asthmatic airways. Am J Respir Crit Care Med 152: 1653-1658, 1995.
35. Faisy C, Pinto F, Danel C, Naline E, Risse PA, Leroy I, Israel-Biet D, Fagon JY, Candenas ML and Advenier C: Beta2-adrenoceptor agonist modulates endothelin-1 receptors in human isolated bronchi. Am J Respir Cell Mol Biol 34: 410-416, 2006.
36. Knight LJ, Burrage J, Bujac SR, Haggerty C, Graham A, Gibson NJ, Ellison G, Growcott JW, Brooks AN, Hugher AM, Xinarianos G, Nikolaidis G, Field JK and Liloglou T: Epigenetic silencing of the endothelin-B receptor gene in non small cell lung cancer. Int J Oncol 34: 465-471, 2009.
37. Demunter A, De Wolf-Peeters C, Degreef H, Stas M and Van den Oord JJ: Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 438: 485-491, 2001.
38. Egidy G, Juillerat-Jeanneret L, Jeannin JF, Korth P, Bosman FT and Pinet F: Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol 157: 1863-1874, 2000.
39. Bagnato A, Spinella F and Rosano L: The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 86: 473-484, 2008.
40. Lalich M, McNee DG, Wilding G and Liu G: Endothelin receptor antagonists in cancer therapy. Cancer Invest 25: 785-794, 2007.
41. Rosano L, Di Castro V, Spinella F, Decandia S, Natali PG and Bagnato A: ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) 231: 1132-1135, 2006.
42. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS and Padley RJ: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20: 2171-2180, 2002.
43. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, Qian J, Steinberg J, Carducci M and Atrasentan phase 3 study group: Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113: 2478-2487, 2008.
44. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D and Dawson NA: Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55: 1112-1123, 2009.
45. Rajeshkumar NV, Rai A and Gulati A: Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 94: 237-247, 2005.
46. Mai HQ, Zeng ZY, Feng KT, Ye YL, Zhang CQ, Liang WJ, Guo X, Mo HY and Hong MH: Therapeutic targeting of the endothelin A receptor in human nasopharyngeal carcinoma. Cancer Sci 97: 1388-1395, 2006.
47. Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger Am, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM and Bepler G: Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 14: 1464-1469, 2008.